Additionally, artemisinin, a ZDHHC6 inhibitor, effectively reduces N-Ras palmitoylation, thereby weakening downstream signaling pathways and providing a potential therapeutic strategy for N-Ras mutant cancers [142]. The gene discussed is NRAS; the disease is cancer.